This review has aimed to highlight the successful treatment of steroid-refractory and steroid-dependent, acute and chronic GvHD with ECP. This novel treatment appears to offer selective ...

Sirolimus is an mTOR inhibitor that healthcare professionals occasionally use alongside steroid therapy in GVHD. ECP uses ultraviolet light to alter the function of white blood cells called ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the donor's immune cells attack the recipient's tissues. Ocular ...

The efficacy of IVIG in preventing GvHD has not been definitely demonstrated clinically. Using a xenogeneic model of GvHD in NOD/SCID/γc− (NSG) mice, we showed that weekly administration of ...

including cutaneous T-cell lymphoma (CTCL), and to treat transplant rejection and graft-versus-host disease (GvHD). ECP involves taking a patient's blood and then isolating and treating abnormal ...

Chronic GvHD can be difficult to cope with. It can affect your quality of life. Find out more about how it might affect you and what support is available. The length of time you have chronic GvHD can ...

Cite this: Technology Insight: ECP for the treatment of GvHD-Can We Offer Selective Immune Control Without Generalized Immunosuppression? - Medscape - Jun 01, 2006. SR Marshall is a ...